Kiadis Pharma receives two orphan drug designations for Reviroc from the FDA

10-Dec-2008 - USA

Kiadis Pharma announces that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc™ Orphan Drug Designations (ODD) for the treatment of two types of non-Hodgkin lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc™ is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

“This is an important strategic milestone in the development of Reviroc™ and we are very pleased with the orphan drug designations received from the FDA”, says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance